JP6707222B2 - ドパミン過感受性精神病の判定方法 - Google Patents
ドパミン過感受性精神病の判定方法 Download PDFInfo
- Publication number
- JP6707222B2 JP6707222B2 JP2015188048A JP2015188048A JP6707222B2 JP 6707222 B2 JP6707222 B2 JP 6707222B2 JP 2015188048 A JP2015188048 A JP 2015188048A JP 2015188048 A JP2015188048 A JP 2015188048A JP 6707222 B2 JP6707222 B2 JP 6707222B2
- Authority
- JP
- Japan
- Prior art keywords
- polymorphism
- dsp
- gene
- risk
- schizophrenia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title claims description 34
- 208000028017 Psychotic disease Diseases 0.000 title claims description 26
- 229960003638 dopamine Drugs 0.000 title claims description 17
- 206010020751 Hypersensitivity Diseases 0.000 title claims description 11
- 208000026935 allergic disease Diseases 0.000 title claims description 11
- 230000009610 hypersensitivity Effects 0.000 title claims description 11
- 238000000034 method Methods 0.000 claims description 53
- 229940079593 drug Drugs 0.000 claims description 36
- 239000003814 drug Substances 0.000 claims description 36
- 201000000980 schizophrenia Diseases 0.000 claims description 33
- 239000002773 nucleotide Substances 0.000 claims description 29
- 125000003729 nucleotide group Chemical group 0.000 claims description 29
- 230000000561 anti-psychotic effect Effects 0.000 claims description 26
- 108091034117 Oligonucleotide Proteins 0.000 claims description 18
- 238000012217 deletion Methods 0.000 claims description 15
- 230000037430 deletion Effects 0.000 claims description 15
- 239000012472 biological sample Substances 0.000 claims description 13
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 108090001111 Dopamine D2 Receptors Proteins 0.000 claims description 8
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims description 8
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims description 8
- 229960001076 chlorpromazine Drugs 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 description 52
- 101150049660 DRD2 gene Proteins 0.000 description 31
- 239000000164 antipsychotic agent Substances 0.000 description 29
- 238000011282 treatment Methods 0.000 description 23
- 229940005529 antipsychotics Drugs 0.000 description 19
- 230000015572 biosynthetic process Effects 0.000 description 15
- 239000000523 sample Substances 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 12
- 238000001514 detection method Methods 0.000 description 12
- 108700028369 Alleles Proteins 0.000 description 10
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 102100020756 D(2) dopamine receptor Human genes 0.000 description 8
- 101000931901 Homo sapiens D(2) dopamine receptor Proteins 0.000 description 8
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000003321 amplification Effects 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 208000031555 Treatment-Resistant Schizophrenia Diseases 0.000 description 6
- 229940127236 atypical antipsychotics Drugs 0.000 description 6
- 229940104302 cytosine Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 101100491147 Homo sapiens ANKK1 gene Proteins 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000003205 genotyping method Methods 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 239000003693 atypical antipsychotic agent Substances 0.000 description 4
- 210000003722 extracellular fluid Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 102000054765 polymorphisms of proteins Human genes 0.000 description 4
- 230000004043 responsiveness Effects 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 3
- 206010071602 Genetic polymorphism Diseases 0.000 description 3
- 101000889403 Homo sapiens Ankyrin repeat and protein kinase domain-containing protein 1 Proteins 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000001447 compensatory effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 208000022610 schizoaffective disease Diseases 0.000 description 3
- 230000005062 synaptic transmission Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 102100039182 Ankyrin repeat and protein kinase domain-containing protein 1 Human genes 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 208000027776 Extrapyramidal disease Diseases 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000002969 morbid Effects 0.000 description 2
- 238000001668 nucleic acid synthesis Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 239000000941 radioactive substance Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 1
- 108010072564 5-HT2A Serotonin Receptor Proteins 0.000 description 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 101000829171 Hypocrea virens (strain Gv29-8 / FGSC 10586) Effector TSP1 Proteins 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 206010041243 Social avoidant behaviour Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 229940035678 anti-parkinson drug Drugs 0.000 description 1
- 229960004372 aripiprazole Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 150000003936 benzamides Chemical class 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- FFSAXUULYPJSKH-UHFFFAOYSA-N butyrophenone Chemical compound CCCC(=O)C1=CC=CC=C1 FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 238000013187 longer-term treatment Methods 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- VRQVVMDWGGWHTJ-CQSZACIVSA-N methotrimeprazine Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1 VRQVVMDWGGWHTJ-CQSZACIVSA-N 0.000 description 1
- 229940042053 methotrimeprazine Drugs 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960004940 sulpiride Drugs 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YDLQKLWVKKFPII-UHFFFAOYSA-N timiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC(N2C(NC3=CC=CC=C32)=S)CC1 YDLQKLWVKKFPII-UHFFFAOYSA-N 0.000 description 1
- 229950000809 timiperone Drugs 0.000 description 1
- 208000029252 treatment-refractory schizophrenia Diseases 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- -1 urine Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
統合失調症(統合失調感情障害を含む)患者421名および健常者341名を検討の対象として比較検討を行った。統合失調症患者は,アメリカ精神医学会出版の精神障害の診断と統計マニュアル第4版テキスト改訂版(DSM−4−TR;diagnostic and statistical manual of mental disorders−IV−text revision)で診断基準を満たすものを選択した。また、健常者は、過去から採血時までにいかなる1軸診断も満たしていないもの、すなわち精神障害を有していないと診断されたものを選択した。
遺伝子型の判定(ジェノタイピング(genotyping)ともいう。)はアプライド バイオシステムズ 300 リアル−タイム PCR システム(Applied Biosystems 7300 Real−Time PCR System;Applied Biosystems社製)を用い、製造者提供のタックマン(登録商標) アレリック ディスクリミネーション プロトコル(Taqman(R) allelic discrimination protocol;Applied Biosystems社製)に従って、タックマン(登録商標) アッセイにより実施した。
フォワードプライマー配列:CAAAACAAGGGATGGCGGAATC(配列番号2)
リバースプライマー配列:CCACCAAAGGAGCTGTACCT(配列番号3)
健常者群と統合失調症(統合失調感情障害を含む)患者群との間で、−141C Ins/Del多型(rs1799732)およびTaq1A多型(rs1800497)共に、遺伝子型およびアレル頻度に有意差を認めなかった。
配列番号2:DRD2遺伝子の−141C Ins/Del多型の検出用フォワードプライマー。
配列番号3:DRD2遺伝子の−141C Ins/Del多型の検出用リバースプライマー。
Claims (7)
- 抗精神病薬がクロルプロマジン換算量で600mg以上投与された被験者の生物学的試料において、ドパミンD2受容体遺伝子プロモーター領域に存在する多型であって、米国国立バイオテクノロジー情報センターのSNPデータベースにrs1799732として登録された1塩基多型を検出することを含む、ドパミン過感受性精神病の罹患リスクの判定方法。
- 前記1塩基多型が欠失多型であるときに、ドパミン過感受性精神病の罹患リスクが高いと判定される、請求項1に記載の判定方法。
- 配列番号2に記載の塩基配列からなるオリゴヌクレオチドおよび配列番号3に記載の塩基配列からなるオリゴヌクレオチドを含むプライマーセットを用いて前記塩1塩基多型を検出することを含む、請求項1または2に記載の判定方法。
- 前記被験者が統合失調症の患者である、請求項1から3のいずれか1項に記載の判定方法。
- 前記生物学的試料が血液である、請求項1から4のいずれか1項に記載の判定方法。
- 配列番号2に記載の塩基配列からなるオリゴヌクレオチドおよび配列番号3に記載の塩基配列からなるオリゴヌクレオチドを含む、抗精神病薬がクロルプロマジン換算量で600mg以上投与された統合失調症患者のドパミン過感受性精神病の罹患リスクの判定用試薬キット。
- 統合失調症の患者の血液において、ドパミンD2受容体遺伝子プロモーター領域に存在する多型であって、米国国立バイオテクノロジー情報センターのSNPデータベースにrs1799732として登録された1塩基多型を検出することを含む、抗精神病薬がクロルプロマジン換算量で600mg以上投与された統合失調症患者群からドパミン過感受性精神病患者群を選別する方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015188048A JP6707222B2 (ja) | 2015-09-25 | 2015-09-25 | ドパミン過感受性精神病の判定方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015188048A JP6707222B2 (ja) | 2015-09-25 | 2015-09-25 | ドパミン過感受性精神病の判定方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017060432A JP2017060432A (ja) | 2017-03-30 |
JP6707222B2 true JP6707222B2 (ja) | 2020-06-10 |
Family
ID=58428470
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015188048A Active JP6707222B2 (ja) | 2015-09-25 | 2015-09-25 | ドパミン過感受性精神病の判定方法 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6707222B2 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6935079B2 (ja) * | 2017-05-09 | 2021-09-15 | 国立大学法人千葉大学 | 機能的snpの組合せ解析 |
-
2015
- 2015-09-25 JP JP2015188048A patent/JP6707222B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2017060432A (ja) | 2017-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2009282114B2 (en) | Method of identifying disease risk factors | |
EP3507384B1 (en) | Methods and composition for the prediction of the activity of enzastaurin | |
US20130274133A1 (en) | Genetic variations in the interleukin-6 receptor gene as predictors of the response of patients to treatment with interleukin-6 receptor inhibitors | |
JP2020089370A (ja) | 抗精神病薬に基づく処置により誘導される錐体外路症状(eps)の発症を予測する方法 | |
Maleki et al. | NOTCH1, SF3B1, MDM2 and MYD88 mutations in patients with chronic lymphocytic leukemia | |
US20210348235A1 (en) | Genetic markers associated with response to crth2 receptor antagonists | |
JP6707222B2 (ja) | ドパミン過感受性精神病の判定方法 | |
MX2014006186A (es) | Capacidad de respuesta a los inhibidores de la angiogenesis. | |
JP5560456B2 (ja) | エルロチニブの副作用又は薬効を判定する方法 | |
JP6644478B2 (ja) | チオプリン製剤による副作用の危険性の判定方法 | |
Ho et al. | Rapid identification of heterozygous or homozygous JAK2V617F mutations in myeloproliferative neoplasms using melting curve analysis | |
KR102650359B1 (ko) | 약물 과민반응 진단용 snp 및 이를 이용한 진단 방법 | |
WO2016123543A1 (en) | Method for treating schizophrenia comprising administering lurasidone | |
EP3464620B1 (en) | Determination of genetic predisposition to aggressive prostate cancer | |
Kheirkhah et al. | Pharmacogenetic Analysis of Taq1A (rs1800497), T102C (rs6313) and His452Tyr (rs6314) with Clozapine Response in First Line Therapy Resistant Schizophrenia Patients in an Iranian Ethnic Group | |
US20130078637A1 (en) | Antipsychotic-induced parkinsonism genotypes and methods of using same | |
Tarbox-Berry et al. | Polymorphisms in the Human Aquaporin 4 Gene Are Associated With Schizophrenia in the Southern Chinese Han Population: A Case–-Control Study | |
AU2013202634B2 (en) | Method of identifying disease risk factors | |
EP4118236A1 (en) | Therapeutic methods for the treatment of subjects with risk alelles in il33 | |
WO2013172922A1 (en) | Lmtk3 genotype analysis for use in predicting outcome and therapy selection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A80 | Written request to apply exceptions to lack of novelty of invention |
Free format text: JAPANESE INTERMEDIATE CODE: A80 Effective date: 20151022 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180830 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190626 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190702 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190827 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200220 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200311 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200402 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6707222 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |